Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats.
Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats.
复制标题
DOI：
10.3892/ijmm.13.4.577
复制
发表时间：
2004-04
影响因子：
5.4
通讯作者：
Y. Araki;A. Andoh;J. Takizawa;W. Takizawa;Y. Fujiyama
中科院分区：
文献类型：
--
作者：
Y. Araki;A. Andoh;J. Takizawa;W. Takizawa;Y. Fujiyama
最近的研究表明，益生菌或短链脂肪酸（SCFA）对炎症性肠道疾病（IBD）患者具有治疗作用。在先前的研究中，我们证明了丁酸梭菌在培养物中产生高水平的SCFAs。此外，一种基于酸奶的添加剂有效地掩盖了，完全消除了来自SCFA的难闻气味。我们最近报道，经口给予丁酸梭菌衍生物的高剂量和低剂量饲料（分别为50% w/w，17天和5% w/w，16个月）不会引起大鼠的病理学异常。在本研究中，我们评价了该产品对葡聚糖硫酸钠（DSS）诱导的大鼠实验性结肠炎的作用。给予5周龄雄性Wistar汉诺威GALAS大鼠含有3%（w/w）DSS的标准饮食的混合物8天。在衍生物喂养组，丁酸梭菌衍生物（20% w/w）与0.1%（w/w）添加剂也被添加到他们的饮食。对照组给予自来水（20%w/w）和0.1%（w/w）添加剂。8天后，进行剖腹手术，并确定宏观和微观炎症评分。酪酸梭菌衍生物有效地预防了血性腹泻。此外，与对照喂养组相比，衍生物喂养组的粘膜损伤在宏观上显著减少。丁酸梭菌衍生物在IBD患者中的潜在临床疗效也进行了讨论。
Recent studies have suggested that probiotics or short chain fatty acids (SCFAs) exert a therapeutic effect on inflammatory bowel disease (IBD) patients. In a previous study, we demonstrated that Clostridium butyricum produces high levels of SCFAs in culture. In addition, a yogurt-based additive effectively masked, completely eliminating the unpleasant odor derived from the SCFAs. We recently reported that the oral administration of both high and low dose diets (50% w/w for 17 days and 5% w/w for 16 months, respectively) of the Clostridium butyricum derivative did not cause pathological abnormalities in rats. In the present study, we evaluated the effects of this product against dextran sulfate sodium (DSS)-induced experimental colitis in rats. Five-week-old male Wistar Hannover GALAS rats were given a mixture of a standard diet containing 3% (w/w) of DSS for 8 days. In the derivative-fed group, Clostridium butyricum derivative (20% w/w) with 0.1% (w/w) additive was also added to their diet. The control-fed group was given tap water (20% w/w) with 0.1% (w/w) additive. After 8 days, a laparotomy was performed, and macroscopic and microscopic inflammation scoring was determined. The Clostridium butyricum derivative effectively prevented bloody diarrhea. In addition, mucosal damage to the derivative-fed group was significantly reduced macroscopically compared to that of the control-fed group. The potential clinical efficacy of the Clostridium butyricum derivative in IBD patients is also discussed.